The new production units will cover an area of 7.000 m² and make conditions for the creation of about 200 new jobs.
The commitment to permanent growth and development, as well as following the trends and the latest developments in the field of pharmacy, are the main reasons why Alkaloid AD Skopje has maintained a continuous investment rate over the past twenty years, investing over EUR 200 million, allocated mainly in Pharmacy segment. Alkaloid's management considers the investment ventures in: manufacturing facilities and equipment, laboratories, research and development institute, quality control center, modern SAP software, technology and well-trained staff to be necessary prerequisites for increased placements on the market and intensified global positioning of Alkaloid brand products. In this regard, investments in new production units are carried out, amounting to EUR 11 million and which, like others, will be carried out in accordance with the strict requirements of Good Manufacturing Practice (GMP).
EUR 3.5 million of the planned EUR 11 million will be intended for full technological development of the Solid Form Packaging unit, covering an area of 2.000m². Technical and technological equipment has been ordered for the needs of the department, valued at EUR 5.2 million, including two automatic packing lines. EUR 2.3 million will be invested in the construction of two new floors intended for the production of solid pharmaceutical forms and an accompanying space for technical and technological equipment, covering a total area of 5,000 m².
All of this will increase production capacity by at least 50%, thus rising from the current capacity of almost 2 billion tablets and capsules annually to more than 3 billion pieces of solid pharmaceutical forms.
"In line with the developmental strategy and long-term capital investment plan, Alkaloid is launching a new phase in investment activities aimed at increasing the company's production capacity. The planned investment is in line with the company's policy of investing in capital projects, and given the triple increase in consolidated sales revenue over the past 15 years, such a venture has been necessary to enable more intense placements on the market and continued growth”, said Zhivko Mukaetov, CEO and Chairman of the Board of Directors of the company.
The completion of this investment, planned for the first half of 2020, will make conditions for the creation of about 200 new jobs in the Pharmacy segment.